Introduction to Retatrutide Phase 3 Clinical Trial
A recent phase 3 clinical trial, funded by Eli Lilly, evaluated the effectiveness of retatrutide as a new weight-loss solution. The trial results, published in the National Library of Medicine on September 29, indicate that retatrutide led to substantial weight reduction among participants. The demand for anti-obesity medications continues rising, pressuring drug manufacturers to develop treatments beyond current GLP-1 therapies, such as Wegovy and Ozempic.
Overview of Retatrutide
Retatrutide is a weight-loss drug that targets three hormone receptors differently from GLP-1-based treatments like Wegovy and Ozempic. These traditional therapies mimic the GLP-1 hormone to prolong the feeling of fullness, reducing food intake. Retatrutide targets GIP and glucagon, in addition to GLP-1, potentially boosting energy expenditure and fat burning, contributing to the increased weight loss observed in trials. Retatrutide is administered via injection, similar to GLP-1 drugs, which may also be available as daily pills.
Clinical Trials Insights and Results
The clinical trial conducted by Eli Lilly involved 2,339 obese adults without diabetes over 18 months. Some participants suffered from knee osteoarthritis and obstructive sleep apnea. They were randomly assigned doses of 4 mg, 9 mg, 12 mg, or a placebo. The trial showed significant weight loss in all retatrutide participants:
- 4 mg dose group: 17.6% reduction in body weight
- 9 mg dose group: 23.7% reduction
- 12 mg dose group: 25% reduction
Placebo participants experienced a 3.9% weight reduction. Eli Lilly’s study also noted improvements in knee pain and sleep apnea conditions. Side effects were primarily gastrointestinal.
Despite its promising results, retatrutide is still experimental and has not received FDA approval. Eli Lilly plans to seek regulatory approval but no date is set. Additional trials are ongoing. Retatrutide remains available solely through Eli Lilly’s clinical trials. The company warns against purchasing unregulated products due to possible harmful contaminants, inaccurate dosing, or incorrect ingredients.
Issues Surrounding Retatrutide’s Availability and Safety
Although not FDA-approved, people obtain retatrutide from various sources, including online, convenience stores, and medical professionals, as reported by CBS News. Eli Lilly emphasizes the investigational status of retatrutide and advises against using products outside their trials due to unknown risks.
Dr. Brian Wojeck from Yale Medicine cautions against using compounded agents, which are unstudied and may result in adverse events like hospitalization. He does not manage such agents.
Concerns Over Reported Deaths
CBS News reported two deaths linked to black-market retatrutide. In July, a woman suffered cardiac arrest and died after using a drug marketed as retatrutide. Another September death involved a person who purchased retatrutide online after a nurse’s persuasion. These deaths were unrelated to Eli Lilly’s trials.